180 Life Sciencesの簿価
180 Life Sciencesの簿価 は何ですか。
180 Life Sciences Corp.の簿価 は-0.02です。
簿価 の定義は何ですか。
1株当たりの帳簿価額は、会社の資産から会社の負債を差し引いた数を発行済株式数で割ったものです。
The book value of a company is the value of its assets according to its balance sheet account balance. For assets, the value is based on the original cost of the asset less any depreciation, amortization or impairment costs made against the asset. Traditionally, a company's book value is its total assets minus intangible assets and liabilities. However, in practice, depending on the source of the calculation, book value may variably include goodwill, intangible assets, or both. The value inherent in its workforce, part of the intellectual capital of a company, is always ignored. The book value of a company may be also referred as with the term net asset value.
The book value per share is the the balance sheet equity value divided by the number of shares outstanding at the date of the balance sheet. Book value per share can be used to generate a measure of comprehensive earnings, when the opening and closing values are reconciled. The sale of shares/units by a business increases the total book value. Book value per share will increase if the additional shares are issued at a price higher than the pre-existing book value per share. The purchase of its own shares by a business will decrease total book value. Book value per share will decrease if more is paid for them than was received when originally issued. Dividends paid out will decrease book value per share value.
NASDAQのセクタHealth Careにおける簿価 の企業と比べる180 Life Sciences
180 Life Sciencesは何をしますか。
180 Life Sciences Corp., a clinical-stage biotechnology company, engages in the development of novel drugs for unmet medical needs in chronic pain, inflammation, inflammatory diseases, and fibrosis. Its product development platforms in Phase IIb/III clinical trials include Fibrosis and anti-tumour necrosis factor (Anti-TNF) platform, which focuses on fibrosis and Anti-TNF; Synthetic Cannabidiol (CBD) Analogs platform, which are man-made derivatives of CBD; and a7nAChR platform, which focuses on alpha 7 nicotinic acetylcholine receptor. The company was incorporated in 2016 and is headquartered in Palo Alto, California.
180 Life Sciencesと類似の簿価
- Proteoの簿価 は-0.02です。
- HFXの簿価 は-0.02です。
- Aequus Pharmaceuticalsの簿価 は-0.02です。
- Shekel Brainweighの簿価 は-0.02です。
- Pascal Biosciencesの簿価 は-0.02です。
- Globally Local Technologiesの簿価 は-0.02です。
- 180 Life Sciencesの簿価 は-0.02です。
- Duesenberg Technologiesの簿価 は-0.02です。
- Memexの簿価 は-0.02です。
- Branded Legacy Incの簿価 は-0.02です。
- Synstreamの簿価 は-0.02です。
- BioPharmXの簿価 は-0.02です。
- Achiko AGの簿価 は-0.02です。